{"analyses":[{"ciLowerLimit":"0.50","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.79","estimateComment":"Hazards ratio estimate is based on a Cox´s model stratified by IPI risk and stage of disease. A hazard ratio \\< 1 indicates an advantage for VcR-CAP.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalComment":"Based on Log rank test stratified with International Prognostic Index (IPI) risk and stage of disease.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"365.0","upperLimit":"513.0","value":"437.0"},{"groupId":"OG001","lowerLimit":"604.0","upperLimit":"969.0","value":"751.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"243"}],"units":"Participants"}],"description":"PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, Vincristine 1.4 mg/m\\^2 and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles Vincristine: Vincristine intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles.","id":"OG000","title":"R-CHOP"},{"description":"Rituximab 375 mg/m\\^2, Cyclophosphamide 750 mg/m\\^2, Doxorubicin 50 mg/m\\^2, VELCADE 1.3 mg/m\\^2, and Prednisone 100 mg/m\\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day of a 21 day (3 week) cycle for 6 cycles VELCADE: VELCADE intravenous on Days 1,4,8, and 11 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles.","id":"OG001","title":"VcR-CAP"}],"paramType":"MEDIAN","populationDescription":"The population consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"Median duration of follow-up of 40 months","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Days"}